Responses
Other responses
Jump to comment:
- Published on: 17 March 2023
- Published on: 17 March 2023
- Published on: 17 March 2023
- Published on: 17 March 2023
- Published on: 17 March 2023
- Published on: 17 March 2023
- Published on: 17 March 2023Revisiting the Research on Flavor Bans and Youth Smoking: A Response to Liu et al (2022)
NOT PEER REVIEWED
On March 17th, 2021, Tobacco Control published a paper online revealing that the 2019 wave of the Youth Risk Behavior Surveillance System (YRBSS) in San Francisco was fielded in the fall of 2018, as opposed to spring of 2019 as is typical for that survey. [1] On March 21st 2022, I received confirmation from San Francisco’s YRBSS site coordinator that the 2019 wave was fielded from November 5th, 2018 to December 14th, 2018. I appreciate Liu and colleagues bringing this to light. However, their claim that this information invalidates the findings from my 2021 JAMA Pediatrics paper [2] —linking San Francisco’s ban on sales of flavored tobacco and nicotine products to increases in youth cigarette smoking—is both methodologically and historically inaccurate: it overlooks both the assumptions required for difference-in-differences research designs and the full timeline of San Francisco’s flavor ban implementation.In its simplest form, a difference-in-difference (DD) analysis of a particular policy compares outcomes in jurisdictions that did vs. did not adopt the policy, before vs. after that policy officially went into effect (See Figure at https://figshare.com/articles/figure/Figure_1_BasicDDExplanation_pdf/203...). If time-trends in the adopting and non-adopting jurisdictions’ outcomes were parallel in the pre-policy period, the non-adopters’ trends are c...
Show MoreConflict of Interest:
None declared. - Published on: 17 March 2023In reply: Youth tobacco use before and after flavoured tobacco sales restrictions in Oakland, California and San Francisco, California
NOT PEER REVIEWED
Show More
These arguments by Pesko and Friedman cannot undo the central flaw in the Friedman paper. We are surprised that Pesko and Friedman continue to argue that Friedman’s analysis of the YRBSS fall data as “after” data is valid despite the Friedman paper defining the exposure variable as follows: “A binary exposure variable captured whether a complete ban on flavoured tobacco product sales was in effect in the respondent’s district on January 1 of the survey year.”[1] If Friedman had intended to treat the period immediately after July 21 2018 as the “after” period, why had she not selected July 21 of each year as the cut-off date for indicating exposure to the policy effects? It seems apparent that Friedman chose the January 1, 2019 as the cut-off for “after” data because she knew this was the enforcement date and she assumed wrongly that the YRBSS data were collected after January 1, 2019. This is evident in her own response[2] to a critique[3] of her paper as we already noted in our previous response.[4]
Friedman states that “the official/legislated effective date are used to ensure that resulting estimates capture unconfounded responses to the policy change.” Again, if this approach made sense in the specific San Francisco case, why did Friedman use January 1, 2019 in her paper? Perhaps because it simply doesn’t make sense to attribute a policy’s effects before the policy is actually implemented. Similarly, the use of enforcement date rather than...Conflict of Interest:
Name: Jessica Liu
ORCID: 0000-0002-8455-0127
Position: PhD Candidate in Population Health Sciences, Harvard T.H. Chan School of Public
Health
Date: May 10, 2022
I have read and understood BMJ’s policy on declaration of interests and declare the following:
Personal financial interests: None to declare.
Organisational financial interests: Within the last 5 years I have received grant funding from the
National Cancer Institute (Grant # T32CA057711-27) and Harvard T.H. Chan School of Public
Health.
Non-financial interests: None to declare.
Interests of related parties: None to declare.
Interests of related parties: None to declare.
Name: Andy SL Tan
ORCID: http://orcid.org/0000-0001-6459-6171
Position: Associate Professor, University of Pennsylvania, Philadelphia
Date: 5/10/2022
I have read and understood BMJ’s policy on declaration of interests and declare the following:
Personal financial interests: Since 2020, I am a faculty employee of the University of
Pennsylvania Annenberg School for Communication, Philadelphia. From 2014-2020, I was a
faculty employee of the Dana-Farber Cancer Institute and the Harvard TH Chan School of
Public Health. I have received honoraria from the California Tobacco-Related Disease Research
Program (serving on a research study section), Memorial Sloan Kettering Cancer Center
(invited speaker), Rutgers University (invited speaker), Stanford University (invited speaker),
Johns Hopkins University (guest lecturer), American Institutes of Research (for contribution to
the 2020 Surgeon General’s Report), the TCC Group (advisory board member for a COVID-19
study among young adults), and the Society For Personality And Social Psychology (invited
panelist). I have received travel reimbursements from Johns Hopkins University (invited
speaker), the Aetna Foundation (to attend a conference), the Society for Research in Nicotine
and Tobacco Health Equity Network (to attend the annual meeting), and the National Cancer
Institute (to attend an invited workshop).
Organisational financial interests: Within the last 5 years I have received grant funding from
the National Cancer Institute, National Institute on Drug Abuse, and the National Health, Lung,
and Blood Institute (National Institutes of Health), the US Food and Drug Administration Center
for Tobacco Products, the US Centers for Disease Control and Prevention (CDC), and Cancer
Research UK. I do not and have never received any financial support from any tobacco industry
companies, vape product companies, or tobacco industry affiliated organizations.
Non-financial interests: I have published or collaborated on research with over 50 colleagues,
postdoctoral fellows and students.
Interests of related parties: None to declare.
Dr. Hartmann:
Personal financial interests: None to declare.
Organizational financial interests: I have not received any grant funding within the last five years.
Non-financial interests: None to declare
Dr. Winickoff:
ORCID: https://orcid.org/0000-0001-6126-9095
Positions: Professor of Pediatrics Harvard Medical School, Professor of Pediatrics MassGeneral Hospital for Children, Practicing Pediatrician Pediatric Group Practice MGH, Director Pediatric Research MGH Tobacco Research and Treatment Center, Director of Translational Research American Academy of Pediatrics Richmond Center.
Date: May 15, 2022
I have read and understood BMJ’s policy on declaration of interests and declare the following:
Personal financial interests: I have worked at MGH as practicing general pediatrician for over 20 years. Over the past 25 years, I have received grants from the following governmental and non-profit organizations: NIH, NCI, NIDA, NHLBI, AHRQ, Robert Wood Johnson Foundation, Flight Attendant Medical Research Institute, The American Legacy Foundation, and the Medical Foundation. I have received travel/accommodation expenses and consulting fees or honoraria from the World Health Organization (for serving as a Senior Policy Fellow while on sabbatical in Switzerland), U.S. Centers for Disease Control (for consulting on Communities Putting Prevention to Work grants), NIH (for serving as a grant proposal reviewer), the American Academy of Pediatrics (for serving as the Director of Translational Research of the Richmond Center). I have also received travel/accommodation expenses and honoraria for speaking to various public health groups. In addition, I have received funding for serving as an expert witness in legal cases against the tobacco industry.
Organisational financial interests: I have been the PI or Co-PI on multiple NIH R01s in the past 5 years. I have been Co-Investigator on multiple NIH grants in the past 5 years. I do not and have never received any financial support from any tobacco industry companies, vape product companies, or tobacco industry affiliated organizations.
Non-financial interests: I have published or collaborated on research with more than 50 colleagues, postdoctoral fellows and students. I have served as a scientific advisor to the Massachusetts Tobacco Control Program, Massachusetts Attorney General’s Office, Indiana Tobacco Control Program, North Carolina Tobacco Control Program, Head Start, WIC, the Food and Drug Administration, Department of Housing and Urban Development, the National Academy of Medicine, and the U.S. Surgeon General through the Interagency Committee on Smoking and Health. I testified before the U.S. Congress about the adolescent vaping epidemic.
Interests of related parties: None to declare.
- Published on: 17 March 2023Friedman's Use of a Pre-Post Study Design was Appropriate
NOT PEER REVIEWED
Show More
After seeing the response from the authors of “Youth tobacco use before and after flavored tobacco sales restrictions in Oakland, California and San Francisco, California” to the Rapid Response, “Scientific Concerns,” I was dismayed by the reply of the authors that dismissed the efforts of fellow scientists to rigorously discern the effects of flavored tobacco sales restrictions. The central point of their critique of Friedman’s paper is that it only contains pre-flavored tobacco product sales ban datapoints. Hence, a pre-post difference-in-differences design is inappropriate. Friedman most certainly had post-data in her sample. Despite the criticisms from Liu et al, they have not unseated her primary contribution; after a policy change, youth tobacco use behavior in San Francisco changed. Liu et al. provide no rigorous counter-analysis on this point. The author’s argument that no behavior had changed in San Francisco during YBRSS data collection in late 2018 falls apart at close inspection.
First, Liu et al. claim the flavored tobacco sales ban was not yet affecting retailer behavior in late 2018. This question is binary; it can either be answered yes or no. As of July 21, 2018, it was not legal to sell flavored tobacco products in San Francisco. No grace period was in place. Sales of all prohibited flavored products plummeted in the months after the policy became effective (Gammon et al., 2021 ; Table S1). However, sales did not reach zero,...Conflict of Interest:
Dr. Liber has received grants from the Norwegian Cancer Society, the US Food and Drug Administration, and the US National Cancer Institute; consulting fees from Johns Hopkins University and the Brazilian Health Regulatory Agency; and speaker’s fees from the World Health Organization. He was previously employed by the American Cancer Society. - Published on: 17 March 2023Remaining scientific concerns unaddressed by authors
NOT PEER REVIEWED
Show More
In their response to my reply, the authors appear to not address mistakes in their analysis. It's important that any inaccurate statements be corrected for the benefit of other researchers trying to learn from this conversation. 1) The authors say in their response (and the paper) that there is no "after" period in the Friedman study. However, as reported by Gammon et al. (2022), there was an immediate decline in e-cigarette sales in San Francisco at the effective date. The authors need to explain how they can say there is no "post" period if other research clearly shows that e-cigarette sales declined starting July 2018. This is a central part of their argument and the paper unravels if there actually is a reduction in July 2018 as has been documented previously. The authors mention in their reply that they are aware of changes beginning in July 2018 ("merchant education and issuing implementing regulations"). The press may also have widely covered the effective date, which led to changes in youth's demand for e-cigarettes. Many retailers may have wished to become compliant immediately rather than wait until enforcement. All of these are valid potential mechanisms explaining why e-cigarette sales declined starting July 2018. So for the authors to say that Friedman doesn't have a "post" period is ignorant of both the literature and many valid reasons explaining why e-cigarette sales declined at...Conflict of Interest:
I have never accepted tobacco industry funding. Over the past 10 years I have received funding from the National Institutes of Health, American Cancer Society, Centers for Disease Control and Prevention, World Health Organization, Agency for Healthcare Research and Quality, Virginia Foundation for Healthy Youth, and the University of Kentucky’s Institute for the Study of Free Enterprise. - Published on: 17 March 2023In Reply: Youth tobacco use before and after flavoured tobacco sales restrictions in Oakland, California and San Francisco, California
Pesko’s central argument is that it does not matter that Friedman’s assessment of the effect of San Francisco’s ban on the sale of flavored tobacco products is not based on any data collected after the ban actually went into force. In particular, Friedman’s “after” data were collected in fall 2018, before the ordinance was enforced on January 1, 2019.[1] Pesko incredibly argues that Friedman’s “before-after” difference-in-difference analysis is valid despite the fact that she does not have any “after” data.
Pesko justifies this position on the grounds that the effective date of the San Francisco ordinance was July, 2018. While this is true, it is a matter of public record that the ordinance was not enforced until January 1, 2019 because of the need for time for merchant education and issuing implementing regulations.[2]
Friedman is aware of the fact that the enforcement of the ordinance started on January 1, 2019 and used that date in her analysis. In her response[3] to critiques[4] of her paper, she stated “retailer compliance jumped from 17% in December 2018 to 77% in January 2019 when the ban went into effect.” Friedman thought the YRBSS data was collected in Spring 2019; she only learned that the “2019” San Francisco YRBSS data she used were in fact collected in fall 2018 from our paper.[1]
Rather than simply accepting this as an honest error and suggesting Friedman withdraw her paper, Pesko is offering an after-the-fact justification for the cl...
Show MoreConflict of Interest:
Name: Jessica Liu
ORCID: 0000-0002-8455-0127
Position: PhD Candidate in Population Health Sciences, Harvard T.H. Chan School of Public
Health
Date: May 10, 2022
I have read and understood BMJ’s policy on declaration of interests and declare the following:
Personal financial interests: None to declare.
Organisational financial interests: Within the last 5 years I have received grant funding from the
National Cancer Institute (Grant # T32CA057711-27) and Harvard T.H. Chan School of Public
Health.
Non-financial interests: None to declare.
Interests of related parties: None to declare.
Interests of related parties: None to declare.
Name: Andy SL Tan
ORCID: http://orcid.org/0000-0001-6459-6171
Position: Associate Professor, University of Pennsylvania, Philadelphia
Date: 5/10/2022
I have read and understood BMJ’s policy on declaration of interests and declare the following:
Personal financial interests: Since 2020, I am a faculty employee of the University of
Pennsylvania Annenberg School for Communication, Philadelphia. From 2014-2020, I was a
faculty employee of the Dana-Farber Cancer Institute and the Harvard TH Chan School of
Public Health. I have received honoraria from the California Tobacco-Related Disease Research
Program (serving on a research study section), Memorial Sloan Kettering Cancer Center
(invited speaker), Rutgers University (invited speaker), Stanford University (invited speaker),
Johns Hopkins University (guest lecturer), American Institutes of Research (for contribution to
the 2020 Surgeon General’s Report), the TCC Group (advisory board member for a COVID-19
study among young adults), and the Society For Personality And Social Psychology (invited
panelist). I have received travel reimbursements from Johns Hopkins University (invited
speaker), the Aetna Foundation (to attend a conference), the Society for Research in Nicotine
and Tobacco Health Equity Network (to attend the annual meeting), and the National Cancer
Institute (to attend an invited workshop).
Organisational financial interests: Within the last 5 years I have received grant funding from
the National Cancer Institute, National Institute on Drug Abuse, and the National Health, Lung,
and Blood Institute (National Institutes of Health), the US Food and Drug Administration Center
for Tobacco Products, the US Centers for Disease Control and Prevention (CDC), and Cancer
Research UK. I do not and have never received any financial support from any tobacco industry
companies, vape product companies, or tobacco industry affiliated organizations.
Non-financial interests: I have published or collaborated on research with over 50 colleagues,
postdoctoral fellows and students.
Interests of related parties: None to declare.
Dr. Hartmann:
Personal financial interests: None to decalre.
Organizational financial interests: I have not received any grant funding within the last five years.
Non-financial interests: None to declare
Dr. Winickoff:
ORCID: https://orcid.org/0000-0001-6126-9095
Positions: Professor of Pediatrics Harvard Medical School, Professor of Pediatrics MassGeneral Hospital for Children, Practicing Pediatrician Pediatric Group Practice MGH, Director Pediatric Research MGH Tobacco Research and Treatment Center, Director of Translational Research American Academy of Pediatrics Richmond Center.
Date: May 15, 2022
I have read and understood BMJ’s policy on declaration of interests and declare the following:
Personal financial interests: I have worked at MGH as practicing general pediatrician for over 20 years. Over the past 25 years, I have received grants from the following governmental and non-profit organizations: NIH, NCI, NIDA, NHLBI, AHRQ, Robert Wood Johnson Foundation, Flight Attendant Medical Research Institute, The American Legacy Foundation, and the Medical Foundation. I have received travel/accommodation expenses and consulting fees or honoraria from the World Health Organization (for serving as a Senior Policy Fellow while on sabbatical in Switzerland), U.S. Centers for Disease Control (for consulting on Communities Putting Prevention to Work grants), NIH (for serving as a grant proposal reviewer), the American Academy of Pediatrics (for serving as the Director of Translational Research of the Richmond Center). I have also received travel/accommodation expenses and honoraria for speaking to various public health groups. In addition, I have received funding for serving as an expert witness in legal cases against the tobacco industry.
Organisational financial interests: I have been the PI or Co-PI on multiple NIH R01s in the past 5 years. I have been Co-Investigator on multiple NIH grants in the past 5 years. I do not and have never received any financial support from any tobacco industry companies, vape product companies, or tobacco industry affiliated organizations.
Non-financial interests: I have published or collaborated on research with more than 50 colleagues, postdoctoral fellows and students. I have served as a scientific advisor to the Massachusetts Tobacco Control Program, Massachusetts Attorney General’s Office, Indiana Tobacco Control Program, North Carolina Tobacco Control Program, Head Start, WIC, the Food and Drug Administration, Department of Housing and Urban Development, the National Academy of Medicine, and the U.S. Surgeon General through the Interagency Committee on Smoking and Health. I testified before the U.S. Congress about the adolescent vaping epidemic.
Interests of related parties: None to declare.
- Published on: 17 March 2023Scientific concerns
¶ The authors make some points in their article that are reasonable: 1) the generalizability of San Francisco's flavor ban compared to other places is an open question, and 2) the original study uses the San Francisco ban effective date rather than enforcement date. The original author (Friedman), who does not accept tobacco industry funding and is a well-respected scientist in the field, had pointed to both facts in her original article. So that information isn’t new.
Show More
¶ The current authors appear to construct a straw man argument claiming that Friedman argued that she was studying the effect of San Francisco enforcing its flavor ban policy. Friedman specifically wrote in her original article that she was studying, “a binary exposure variable [that] captured whether a complete ban on flavored tobacco product sales was in effect in the respondent’s district on January 1 of the survey year.” She specifically uses effect in the above sentence, so there is no ambiguity that she is studying effective date. San Francisco’s flavor ban effective date was July 2018 (Gammon et al. 2021).
¶ The authors found new information that the San Francisco YRBSS survey was collected between November to December of 2018. Gammon et al. 2021 (Appendix Figure 1) shows that flavored e-cigarette sales declined in San Francisco between the effective date and the end of August 2018 (compensating for a 30-day look-back period for the YRBSS question wording), even though the flavor ban...Conflict of Interest:
I have never accepted tobacco industry funding. Over the past 10 years I have received funding from the National Institutes of Health, American Cancer Society, Centers for Disease Control and Prevention, World Health Organization, Agency for Healthcare Research and Quality, Virginia Foundation for Healthy Youth, and the University of Kentucky’s Institute for the Study of Free Enterprise.